Overexpression of ERα inhibits proliferation and invasion of MKN28 gastric cancer cells by suppressing β-catenin

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1622-1630

  Zhou, Jichun ^a   Teng, Rongyue ^a   Xu, Chaoyang ^c   Wang, Qinchuan ^a   Guo, Jufeng ^a   Xu, Chenpu ^a   Li, Ziduo ^a   Xie, Shuduo ^a   Shen, Jianguo ^a   Wang, Linbo ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b Biomedical Research Center Key Laboratory of Biotherapy of Zhejiang Province   (China)

^c Shaoxing People's Hospital   (China)

Author keywords

ER ; Gastric cancer; Metastasis; MKN28; Proliferation

Indexed keywords

BETA CATENIN; ESTROGEN RECEPTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN MKN28; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; ESTROGEN RECEPTOR ALPHA; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; STOMACH NEOPLASMS;

EID: 84882676684     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2610     Document Type: Article

References (54)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
3. Clarke M, Collins R, Davies C, et al: Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 351: 1451-1467, 1998.
4. Abe O, Abe R, Enomoto K, et al: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 365: 1687-1717, 2005.
5. Tokunaga A, Nishi K, Matsukura N, et al: Estrogen and progesterone receptors in gastric cancer. Cancer 57: 1376-1379, 1986.
6. Bianchi F, Hu J, Pelosi G, et al: Lung cancers detected by screening with spiral computed tomography have a malignant phenotype when analyzed by cDNA microarray. Clin Cancer Res 10: 6023-6028, 2004.
7. Zhang N, Zhang J, Shuai L, et al: Krüppel-like factor 4 negatively regulates β-catenin expression and inhibits the proliferation, invasion and metastasis of gastric cancer. Int J Oncol 40: 2038-2048, 2012.
8. Kouzmenko AP, Takeyama K, Ito S, et al: Wnt/β-catenin and estrogen signaling converge in vivo. J Biol Chem 279: 40255-40258, 2004.
9. Crew KD and Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol 12: 354-362, 2006.
10. Brenner H, Rothenbacher D and Arndt V: Epidemiology of stomach cancer. Methods Mol Biol 472: 467-477, 2009.
11. Parkin D, Whelan S, Ferlay J, Teppo L and Thomas D: Cancer incidence in five continents. Volume VIII. IARC Sci Publ 155: 1-781, 2002.
12. Chandanos E and Lagergren J: Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer 44: 2397-2403, 2008.
13. La Vecchia C, D'Avanzo B, Franceschi S, Negri E, Parazzini F and Decarli A: Menstrual and reproductive factors and gastric-cancer risk in women. Int J Cancer 59: 761-764, 1994.
14. Frise S, Kreiger N, Gallinger S, Tomlinson G and Cotterchio M: Menstrual and reproductive risk factors and risk for gastric adenocarcinoma in women: findings from the Canadian National Enhanced Cancer Surveillance system. Ann Epidemiol 16: 908-916, 2006.
15. Lindblad M, Ye W, Rubio C and Lagergren J: Estrogen and risk of gastric cancer: a protective effect in a nationwide cohort study of patients with prostate cancer in Sweden. Cancer Epidemiol Biomarkers Prev 13: 2203-2207, 2004.
16. Freedman ND, Chow WH, Gao YT, et al: Menstrual and reproductive factors and gastric cancer risk in a large prospective study of women. Gut 56: 1671-1677, 2007.
17. Green J, Czanner G, Reeves G, et al: Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. Int J Cancer 130: 2387-2396, 2012.
18. Lindblad M, García Rodríguez LA, Chandanos E and Lagergren J: Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer 94: 136-141, 2006.
19. Chandanos E, Lindblad M, Jia C, Rubio CA, Ye W and Lagergren J: Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. Br J Cancer 95: 118-122, 2006.
20. Chandanos E, Lindblad M, Rubio CA, et al: Tamoxifen exposure in relation to gastric adenocarcinoma development. Eur J Cancer 44: 1007-1014, 2008.
21. Harrison JD, Watson S and Morris DL: The effect of sex hormones and tamoxifen on the growth of human gastric and colorectal cancer cell lines. Cancer 63: 2148-2151, 1989.
22. Takano N, Iizuka N, Hazama S, Yoshino S, Tangoku A and Oka M: Expression of estrogen receptor-α and -β mRNAs in human gastric cancer. Cancer Lett 176: 129-135, 2002.
23. Furukawa H, Iwanaga T, Koyama H and Taniguchi H: Effect of sex hormones on carcinogenesis in the stomachs of rats. Cancer Res 42: 5181-5182, 1982.
24. Campbell-Thompson M, Lauwers GY, Reyher KK, Cromwell J and Shiverick KT: 17β-estradiol modulates gastroduodenal preneoplastic alterations in rats exposed to the carcinogen N-methyl-N'-nitro-nitrosoguanidine. Endocrinology 140: 4886-4894, 1999.
25. Furukawa H, Iwanaga T, Hiratsuka M, et al: Suppressive effect of sex hormones on spreading of stomach cancer. Gan To Kagaku Ryoho 16: 3691-3695, 1989 (In Japanese).
26. Furukawa H, Iwanaga T, Koyama H and Taniguchi H: Effect of sex hormones on the experimental induction of cancer in rat stomach - a preliminary study. Digestion 23: 151-155, 1982.
27. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y and Shine J: Sequence and expression of human estrogen receptor complementary DNA. Science 231: 1150-1154, 1986.
28. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S and Gustafsson JA: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93: 5925-5930, 1996.
29. Green S, Walter P, Kumar V, et al: Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320: 134-139, 1986.
30. Wu CW, Chang YF, Yeh TH, et al: Steroid hormone receptors in three human gastric cancer cell lines. Dig Dis Sci 39: 2689-2694, 1994.
31. Karat D, Brotherick I, Shenton BK, Scott D, Raimes SA and Griffin SM: Expression of oestrogen and progesterone receptors in gastric cancer: a flow cytometric study. Br J Cancer 80: 1271-1274, 1999.
32. Chandanos E, Rubio CA, Lindblad M, et al: Endogenous estrogen exposure in relation to distribution of histological type and estrogen receptors in gastric adenocarcinoma. Gastric Cancer 11: 168-174, 2008.
33. Matsui M, Kojima O, Uehara Y and Takahashi T: Characterization of estrogen receptor in human gastric cancer. Cancer 68: 305-308, 1991.
34. Wu CW, Lui WY, P'eng FK and Chi CW: Hormonal therapy for stomach cancer. Med Hypotheses 39: 137-139, 1992.
35. Machado JC, Carneiro F, Gärtner F, Ribeiro P and Sobrinho-Simões M: Female sex hormone receptors are not involved in gastric carcinogenesis. A biochemical and immunohistochemical study. Eur J Cancer Prev 3: 31-37, 1994.
36. Singh S, Poulsom R, Wright NA, Sheppard MC and Langman MJ: Differential expression of oestrogen receptor and oestrogen inducible genes in gastric mucosa and cancer. Gut 40: 516-520, 1997.
37. Xu CY, Guo JL, Jiang ZN, et al: Prognostic role of estrogen receptor α and estrogen receptor β in gastric cancer. Ann Surg Oncol 17: 2503-2509, 2010.
38. Gan L, He J, Zhang X, et al: Expression profile and prognostic role of sex hormone receptors in gastric cancer. BMC Cancer 12: 566, 2012.
39. Kitaoka H: Sex hormone dependency and endocrine therapy in diffuse carcinoma of the stomach]. Gan To Kagaku Ryoho 10: 2453-2460, 1983 (In Japanese).
40. Matsui M, Kojima O, Kawakami S, Uehara Y and Takahashi T: The prognosis of patients with gastric cancer possessing sex hormone receptors. Surg Today 22: 421-425, 1992.
41. Zhao XH, Gu SZ, Liu SX and Pan BR: Expression of estrogen receptor and estrogen receptor messenger RNA in gastric carcinoma tissues. World J Gastroenterol 9: 665-669, 2003.
42. Yokozaki H, Takekura N, Takanashi A, Tabuchi J, Haruta R and Tahara E: Estrogen receptors in gastric adenocarcinoma: a retrospective immunohistochemical analysis. Virchows Arch A Pathol Anat Histopathol 413: 297-302, 1988.
43. Wang M, Pan JY, Song GR, Chen HB, An LJ and Qu SX: Altered expression of estrogen receptor α and β in advanced gastric adenocarcinoma: correlation with prothymosin α and clinicopathological parameters. Eur J Surg Oncol 33: 195-201, 2007.
44. Kitaoka H: Chemo-endocrine therapy of diffuse carcinoma of the stomach and its clinical evaluation. Gan No Rinsho 31: 1189-1194, 1985 (In Japanese).
45. Koullias GJ, Pratsinis CI, Korkolis DP, et al: Brief tamoxifen pretreatment enhances the chemosensitivity of gastric carcinoma cells to 5-fluorouracil in vitro. Anticancer Res 23: 1575-1580, 2003.
46. Matsuyama S, Ohkura Y, Eguchi H, et al: Estrogen receptor β is expressed in human stomach adenocarcinoma. J Cancer Res Clin Oncol 128: 319-324, 2002.
47. Ryu WS, Kim JH, Jang YJ, et al: Expression of estrogen receptors in gastric cancer and their clinical significance. J Surg Oncol 106: 456-461, 2012.
48. Ozawa M, Ringwald M and Kemler R: Uvomorulin-catenin complex formation is regulated by a specific domain in the cytoplasmic region of the cell adhesion molecule. Proc Nat Acad Sci USA 87: 4246-4250, 1990.
49. Conacci-Sorrell M, Simcha I, Ben-Yedidia T, Blechman J, Savagner P and Ben-Ze'ev A: Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of β-catenin signaling, Slug, and MAPK. J Cell Biol 163: 847-857, 2003.
50. Logan CY and Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20: 781-810, 2004.
51. Kanwar SS, Yu Y, Nautiyal J, Patel BB and Majumdar AP: The Wnt/β-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer 9: 212, 2010.
52. Hervieu V, Lepinasse F, Gouysse G, et al: Expression of β-catenin in gastroenteropancreatic endocrine tumours: a study of 229 cases. J Clin Pathol 59: 1300-1304, 2006.
53. Lin SY, Xia W, Wang JC, et al: β-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Nat Acad Sci USA 97: 4262-4266, 2000.
54. Wong SC, Lo ES, Lee KC, Chan JK and Hsiao WL: Prognostic and diagnostic significance of β-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res 10: 1401-1408, 2004.